By selecting EGFR-TKI resistant lung cancer cells in vitro, we could monitor changes in CEA heterogeneity in CEA-positive lung adenocarcinoma cells during gefitinib treatment. The gene discussed is CEACAM5; the disease is lung carcinoma.